CN112189013A - 有机化合物 - Google Patents

有机化合物 Download PDF

Info

Publication number
CN112189013A
CN112189013A CN201980034445.2A CN201980034445A CN112189013A CN 112189013 A CN112189013 A CN 112189013A CN 201980034445 A CN201980034445 A CN 201980034445A CN 112189013 A CN112189013 A CN 112189013A
Authority
CN
China
Prior art keywords
pde1
cancer
alkyl
tumor
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980034445.2A
Other languages
English (en)
Chinese (zh)
Inventor
L·P·文诺格勒
J·亨德里克
R·戴维斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intra Cellular Therapies Inc
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of CN112189013A publication Critical patent/CN112189013A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201980034445.2A 2018-05-25 2019-05-24 有机化合物 Pending CN112189013A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862676638P 2018-05-25 2018-05-25
US62/676,638 2018-05-25
US201862688641P 2018-06-22 2018-06-22
US62/688,641 2018-06-22
PCT/US2019/033941 WO2019227004A1 (en) 2018-05-25 2019-05-24 Organic compounds

Publications (1)

Publication Number Publication Date
CN112189013A true CN112189013A (zh) 2021-01-05

Family

ID=68616034

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980034445.2A Pending CN112189013A (zh) 2018-05-25 2019-05-24 有机化合物

Country Status (11)

Country Link
US (1) US20210205310A1 (https=)
EP (2) EP4520399A3 (https=)
JP (1) JP7493460B2 (https=)
KR (1) KR20210013214A (https=)
CN (1) CN112189013A (https=)
AU (1) AU2019275453B2 (https=)
BR (1) BR112020024037A2 (https=)
CA (1) CA3099283A1 (https=)
IL (2) IL278935B2 (https=)
MX (1) MX2020012628A (https=)
WO (1) WO2019227004A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020146384A1 (en) 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds
MX2024010993A (es) * 2022-03-11 2024-09-17 Intra Cellular Therapies Inc Compuestos organicos.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690935A (en) * 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
US20140194396A1 (en) * 2011-06-10 2014-07-10 Intra-Cellular Therapies, Inc. Organic compounds
CN103930132A (zh) * 2011-09-27 2014-07-16 拜奥迈德瓦利探索有限公司 治疗胶质瘤的组合物和方法
CN105377846A (zh) * 2013-03-15 2016-03-02 细胞内治疗公司 有机化合物
US20170197974A1 (en) * 2014-06-20 2017-07-13 Intra-Cellular Therapies, Inc. Organic compounds
CN107106563A (zh) * 2014-09-17 2017-08-29 细胞内治疗公司 化合物和方法
WO2018093591A1 (en) * 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005289891A (ja) * 2004-03-31 2005-10-20 Zen Kubohara Ｐｄｅ１阻害剤
US7783679B2 (en) 2005-01-12 2010-08-24 Computer Associates Think, Inc. Efficient processing of time series data
AU2006255028B2 (en) 2005-06-06 2012-04-19 Intra-Cellular Therapies, Inc. Organic compounds
KR20090042227A (ko) 2006-06-06 2009-04-29 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
EP2240028B1 (en) 2007-12-06 2016-07-20 Intra-Cellular Therapies, Inc. Pyrazolopyrimidine-4,6-dione derivatives and their use as pharmaceutical
KR20120012831A (ko) 2007-12-06 2012-02-10 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
BRPI0922809A2 (pt) 2008-12-06 2018-05-29 Intracellular Therapies Inc compostos orgânicos
KR20110103949A (ko) 2008-12-06 2011-09-21 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
MA32942B1 (fr) 2008-12-06 2012-01-02 Intra Cellular Therapies Inc Composes organiques
JP5778582B2 (ja) 2008-12-06 2015-09-16 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EP2367430B1 (en) 2008-12-06 2014-08-13 Intra-Cellular Therapies, Inc. Organic compounds
EP2367431B1 (en) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. Organic compounds
CA2796756A1 (en) 2010-04-22 2011-10-27 Intra-Cellular Therapies, Inc. Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders
WO2011153135A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
WO2011153136A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
EP2576551A4 (en) 2010-05-31 2014-04-16 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
EP2968338B1 (en) * 2013-03-15 2019-01-09 Intra-Cellular Therapies, Inc. Pde1 inhibitors for use in the treatment and/or prevention of cns injuries, and pns diseases, disorders or injuries
US20160045617A1 (en) * 2013-04-10 2016-02-18 Justin C. Lee Treatment of proximal spinal muscular atrophy
TW201609713A (zh) 2013-12-19 2016-03-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之喹唑啉－ｔｈｆ－胺
JP6696904B2 (ja) * 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
TW201611834A (en) 2014-02-07 2016-04-01 Lundbeck & Co As H Hexahydrofuropyrroles as PDE1 inhibitors
KR20160138084A (ko) 2014-04-04 2016-12-02 하. 룬드벡 아크티에셀스카브 Pde1 저해제인 할로겐화된 퀴나졸린-thf-아민
US10131671B2 (en) 2014-08-07 2018-11-20 Intra-Cellular Therapies, Inc. Organic compounds
TW201629064A (zh) 2014-10-10 2016-08-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之三唑並吡酮
TW201643167A (zh) 2015-04-22 2016-12-16 Ｈ 朗德貝克公司 作爲ｐｄｅ１抑制劑之咪唑並三酮
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
TWI729109B (zh) 2016-04-12 2021-06-01 丹麥商Ｈ 朗德貝克公司 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
CN110267908B (zh) 2016-09-12 2023-08-22 麦斯卓微电子(南京)有限公司 Mems致动系统和方法
JP7134168B6 (ja) 2016-09-12 2024-02-02 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
US10918628B2 (en) * 2016-10-11 2021-02-16 Deutsches Zentrum Für Neurodegenerative Erkrankungen E. V. (Dzne) Treatment of synucleinopathies
WO2018073251A1 (en) 2016-10-18 2018-04-26 H. Lundbeck A/S Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors
WO2020146384A1 (en) * 2019-01-07 2020-07-16 Intra-Cellular Therapies, Inc. Organic compounds

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4690935A (en) * 1983-03-31 1987-09-01 Wayne State University Inhibition of tumor growth and metastasis with calcium channel blocker compounds
US20140194396A1 (en) * 2011-06-10 2014-07-10 Intra-Cellular Therapies, Inc. Organic compounds
CN103930132A (zh) * 2011-09-27 2014-07-16 拜奥迈德瓦利探索有限公司 治疗胶质瘤的组合物和方法
CN105377846A (zh) * 2013-03-15 2016-03-02 细胞内治疗公司 有机化合物
US20170197974A1 (en) * 2014-06-20 2017-07-13 Intra-Cellular Therapies, Inc. Organic compounds
CN107106563A (zh) * 2014-09-17 2017-08-29 细胞内治疗公司 化合物和方法
WO2018093591A1 (en) * 2016-11-03 2018-05-24 Juno Therapeutics, Inc. Combination therapy of a cell based therapy and a microglia inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王晨泉;李运曼;马晓慧;: "磷酸二酯酶与疾病相关的药理学研究进展" *

Also Published As

Publication number Publication date
IL278935A (en) 2021-01-31
IL278935B1 (en) 2025-12-01
US20210205310A1 (en) 2021-07-08
WO2019227004A1 (en) 2019-11-28
KR20210013214A (ko) 2021-02-03
EP4520399A3 (en) 2025-03-26
CA3099283A1 (en) 2019-11-28
JP2021525705A (ja) 2021-09-27
EP4520399A2 (en) 2025-03-12
IL322048A (en) 2025-09-01
IL278935B2 (en) 2026-04-01
MX2020012628A (es) 2021-01-29
JP7493460B2 (ja) 2024-05-31
AU2019275453B2 (en) 2023-12-21
EP3802545A4 (en) 2022-03-16
EP3802545A1 (en) 2021-04-14
AU2019275453A1 (en) 2020-12-03
BR112020024037A2 (pt) 2021-02-09

Similar Documents

Publication Publication Date Title
JP2022017495A (ja) 癌を治療するための併用療法
US20250339438A1 (en) Organic compounds
US20240374605A1 (en) Methods of treating cancer
US20110251240A1 (en) Dosing Regimen of Flavopiridol for Treating Cancer
AU2013307383A1 (en) Aminoheteroaryl compounds as MTH1 inhibitors
CN119365196A (zh) 使用杂芳族大环醚化合物治疗实体肿瘤的方法
WO2014082085A1 (en) Use of itk inhibitors for the treatment of cancer
EP4219456A1 (en) Csf1r kinase inhibitor and use thereof
KR20040007485A (ko) 알레르기성 질환과 같은 비만세포계 질병에 대한ｎ-페닐-2-피리미딘아민의 용도
US12599603B2 (en) Methods of treatment
US20250186446A1 (en) Organic compounds
CN112189013A (zh) 有机化合物
JP2024525515A (ja) がんの予防用又は治療用の医薬組成物
RU2811918C2 (ru) Способы лечения раковых заболеваний и опухолей с использованием ингибиторов pde1
JP2021500413A (ja) 一部の肉腫の治療に使用するためのｉｌ−８阻害薬
CN118043053A (zh) 治疗癌症的方法
HK40122851A (en) Organic compounds
KR20220004025A (ko) 종양-선택적 병용 요법
KR20230131934A (ko) 암을 치료하기 위한 조합 치료요법 스케줄
Jamale et al. THE COMBI-TARGETING CONCEPT: DISSECTION OF THE BINARY MECHANISM OF ACTION OF THE COMBI-TRIAZENE SMA41 IN VITRO AND ANTIPROLIFERATIVE EFFECTS IN VIVO

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination